ANVS:NYE-Annovis Bio, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 24.86

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.27M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Address: 1055 Westlakes Drive, Berwyn, PA, United States, 19312

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

USD163.53B 28.27 2.82
ADPT Adaptive Biotechnologies Corpo..

N/A

USD5.88B 43.96 N/A
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD5.20B N/A N/A
RCUS Arcus Biosciences, Inc

N/A

USD2.37B N/A N/A
MYOV Myovant Sciences Ltd

N/A

USD1.99B N/A N/A
ADCT ADC Therapeutics SA

N/A

USD1.75B -99,999.99 N/A
ZYME Zymeworks Inc

N/A

USD1.52B 300.20 N/A
CVM CEL-SCI Corporation

N/A

USD0.79B N/A N/A
RFL Rafael Holdings, Inc

N/A

USD0.51B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90

ETFs Containing ANVS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 279.54% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 279.54% 100% A+ 99% A+
Trailing 12 Months  
Capital Gain 426.69% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 426.69% 100% A+ 99% A+
Trailing 5 Years  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain 4,255.06% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4,255.06% 100% A+ 100% A+
Risk Return Profile  
Volatility (Standard Deviation) 10,888.66% 4% F N/A N/A
Risk Adjusted Return 39.08% 40% F 56% F
Market Capitalization 0.17B 50% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 100% A+
Price/Book Ratio 23.44 23% F 4% F
Price / Cash Flow Ratio -43.49 93% A 96% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -180.82% 17% F 2% F
Return on Invested Capital 2,479.36% 100% A+ 100% A+
Return on Assets -89.86% 11% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.20 86% B 87% B+
Short Percent 1.86% 88% B+ 70% C-
Beta -0.53 92% A- 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.